Investment Summary

Avacta Group PLC is a clinical-stage life sciences company developing innovative cancer therapies and diagnostic products based on its proprietary Affimer and pre|CISION platforms. The company combines a pioneering scientific approach with a clear development strategy targeting both oncology therapeutics and high-value diagnostics. With pipeline programmes progressing through clinical development, a versatile technology platform that enables ongoing Partnership opportunities and a focused operational strategy, Avacta offers leveraged exposure to potential value catalysts. Despite near-term Volatility characteristic of clinical-stage biotech, the long-term opportunity supports our positive view. We rate the shares a Buy for investors comfortable with the higher risk-reward profile inherent in development-stage biotech.

Business Overview

Avacta is headquartered in Wetherby, United Kingdom, and is listed on the London Stock Exchange AIM market. The company operates two complementary segments. The Therapeutics segment is developing pre|CISION-enabled chemotherapy and antibody-based drug conjugates designed to release active drug specifically within the tumour microenvironment, exploiting the upregulation of fibroblast activation protein (FAP) in many solid tumours. Lead programmes include AVA6000, a pre|CISION-enhanced doxorubicin, and additional candidates leveraging the platform across cytotoxic agents and immune-oncology payloads. The Diagnostics segment, operating under the Coris Bioconcept Brand and other heritage businesses, develops, manufactures and sells immunoassays and lateral flow rapid diagnostic tests for clinical microbiology and other applications.

The Affimer technology platform is a proprietary alternative to antibodies, providing engineered scaffold proteins that can be selected for high specificity and affinity against target proteins. Affimers can be used as therapeutic agents, diagnostic reagents and tools for research. The pre|CISION platform is a chemistry platform that enables selective activation of cytotoxic chemotherapy or other agents within FAP-expressing tumour tissue, potentially improving the therapeutic index of established cancer drugs.

Sector Backdrop

The global oncology market continues to expand rapidly, driven by ageing populations, advances in cancer biology, improved diagnostics and a growing arsenal of targeted therapies, immunotherapies and antibody-drug conjugates. Within this market, technologies that improve therapeutic index, by maximising drug activity in tumour tissue while minimising systemic toxicity, are particularly valued. Antibody-drug conjugates have demonstrated the potential of targeted payload delivery, but conventional cytotoxic chemotherapy continues to play an important role in cancer treatment despite well-documented toxicity profiles. Technologies that enable tumour-specific activation of established cytotoxic agents could materially improve patient outcomes while leveraging the validated activity of these drugs. The diagnostics market, particularly clinical microbiology rapid tests, also benefits from continued Demand for fast, accurate point-of-care testing supporting infection management, antimicrobial stewardship and outbreak detection.

Investment Thesis

Our positive view on Avacta rests on several elements. First, the pre|CISION platform represents a scientifically interesting approach to improving the therapeutic index of cytotoxic chemotherapy and other oncology payloads. Tumour-specific activation could deliver a meaningful clinical benefit relative to standard formulations. Second, lead programme AVA6000 has been progressing through clinical development, with data supporting the underlying scientific hypothesis. Third, the Affimer platform provides a versatile technology base for both therapeutic and diagnostic applications, supporting partnership opportunities and licensing optionality. Fourth, the Diagnostics business provides a steady Revenue base from established clinical microbiology products, providing some financial support during the development phase of the therapeutics pipeline. Fifth, the company has been restructuring operations to focus Capital on the highest-conviction programmes, improving efficiency and extending cash runway. Sixth, the valuation reflects significant pessimism on the path forward, providing favourable Leverage to positive clinical and partnership news flow.

Pipeline and Clinical Outlook

AVA6000 is the most advanced therapeutic candidate. The molecule consists of doxorubicin chemically modified to be inactive until cleaved by FAP within tumour tissue. Phase 1 clinical data has demonstrated tumour-specific activation, improved pharmacokinetics and a different toxicity profile relative to conventional doxorubicin. Continued clinical development across multiple solid tumour indications, including soft tissue sarcoma, will support dose-finding, efficacy demonstration and indication selection. Successful Phase 2 data would support broader development and potential partnerships. Additional pipeline programmes leverage the pre|CISION platform across other cytotoxic payloads and immune-oncology agents, providing multiple shots on goal.

Soft tissue sarcoma represents a particularly attractive lead indication for AVA6000. Soft tissue sarcomas are a heterogeneous group of cancers arising from connective tissues, with several subtypes characterised by high FAP expression in the tumour stroma. Conventional doxorubicin is widely used in soft tissue sarcoma but its efficacy is limited by systemic toxicity, including cardiac toxicity that constrains cumulative dosing. If AVA6000 can demonstrate improved efficacy and a better safety profile, it could become an attractive treatment option in a setting with significant unmet need. Beyond soft tissue sarcoma, applications across additional cancers with high FAP stromal expression, including pancreatic cancer, gastric cancer, head and neck cancer and certain breast cancer subtypes, provide additional clinical development opportunities.

The Affimer platform supports a broader pipeline of internally developed therapeutic candidates as well as partnership-based programmes. Affimers offer potential advantages over antibodies including smaller size, improved tissue penetration, stable in vitro performance and amenability to multi-specific engineering. While many Affimer programmes are at earlier stages, the platform provides ongoing optionality including external licensing or partnership opportunities that could deliver near-term value.

Diagnostics Business and Steady Contribution

The Diagnostics segment provides a stabilising commercial contribution to the overall business. Coris Bioconcept is a Belgian-based clinical microbiology rapid test manufacturer with established products including the Crystal VC dual cholera test, Strep B Strip and a broad range of bacterial and parasitological tests used in clinical laboratories worldwide. Continued investment in product development, regulatory clearances and commercial expansion supports steady revenue growth. The Diagnostics business benefits from established customer relationships, recurring purchase patterns and a generally favourable Margin profile. While modest in scale relative to the therapeutic opportunity, the diagnostics contribution helps fund the broader strategic priorities and provides operational ballast.

Financial Performance

Avacta operates with a financial profile typical of a clinical-stage biopharmaceutical company supported by a modest commercial revenue base. Cash Management is a critical focus, with management balancing investment in clinical programmes, operational efficiency and selective business activity. Recent strategic and financial restructuring has prioritised the highest-conviction programmes, optimised the cost base and extended cash runway. Revenue from the Diagnostics business provides some operational cash generation. Clinical and operational milestones, alongside potential partnership transactions, may provide additional sources of capital. Investors should anticipate ongoing operating losses during the clinical development phase, with profitability dependent on successful development, regulatory approval and commercialisation of pipeline candidates or value-creating partnership transactions.

Commercialisation and Partnership Outlook

Avacta's commercialisation strategy is likely to evolve over time. For diagnostic products, the company continues to leverage established commercial channels and partnerships across clinical laboratories worldwide. For therapeutic candidates, the strategy will likely involve a combination of selective partnerships with established pharmaceutical companies and potential in-house commercialisation of niche indications. Partnership opportunities are supported by the platform technology, the clinical data, the broader pipeline and the company's relationships with biopharmaceutical industry contacts. Success in securing partnerships, including potential collaboration with major oncology companies, would represent a meaningful validation event and source of capital.

Strategic Restructuring and Operational Discipline

Avacta has been undertaking strategic and operational restructuring to focus resources on the highest-priority programmes, reduce overhead and extend cash runway. This includes prioritising AVA6000 and selected next-generation pre|CISION programmes, while reducing investment in lower-priority activities. Operational efficiency initiatives across procurement, facilities and headcount support cost discipline. The Leadership team has been strengthened with experienced biopharmaceutical executives, and the board provides additional industry expertise. While restructuring inevitably introduces near-term disruption, the resulting focus and operational efficiency support a more sustainable path forward and increase the probability of successful clinical and commercial outcomes.

Valuation Perspective

Avacta trades on a valuation that reflects significant pessimism about the path forward, providing favourable leverage to positive clinical data, partnership announcements or strategic milestones. Sum-of-the-parts analysis, applying Risk-adjusted probability of success to pipeline programmes and a sensible multiple to the Diagnostics business, points to material upside potential from current levels. The combination of platform optionality, pipeline catalysts and a stabilised commercial base provides a balanced framework for risk-reward assessment. Investors comfortable with higher volatility may find the valuation an attractive entry point for an asymmetric long-term opportunity.

Key Risks

Risks are significant and characteristic of clinical-stage biotech. Clinical Trials may Fail to demonstrate sufficient efficacy or may reveal safety concerns. Regulatory pathways are inherently uncertain. Cash management may require additional fundraising or strategic transactions. Competitive intensity in oncology is high, with multiple companies pursuing similar targets and mechanisms. Manufacturing of complex Biologics and small molecule conjugates introduces operational complexity. Currency, macro and Capital Markets sentiment can have outsized impact on small-cap clinical-stage biotech valuations. Partnership negotiations may not deliver the expected Economics.

Sustainability and Strategic Outlook

Avacta's mission of developing innovative cancer therapies aligns with broader healthcare system goals of improving patient outcomes. Strong governance, ethical clinical trial conduct and patient-focused values support stakeholder engagement. As the company progresses through development milestones, the long-term contribution to oncology and diagnostic innovation provides a meaningful societal value proposition. The combination of mission alignment, scientific innovation and strategic discipline supports a credible long-term outlook for shareholders prepared to look through near-term volatility.

Scientific Platform and Differentiation

The pre|CISION platform represents a meaningful scientific contribution to the broader effort to improve the therapeutic index of cytotoxic chemotherapy. Fibroblast activation protein is highly upregulated in many solid tumours, particularly in the stromal compartment around cancer cells. By engineering payloads that are inactive until cleaved by FAP within the tumour microenvironment, the platform aims to deliver high local concentrations of active drug while limiting systemic exposure. This approach is conceptually similar in spirit to antibody-drug conjugates, which use targeted antibodies to deliver payloads, but the pre|CISION approach leverages enzymatic activation rather than antibody-directed delivery. The technology has potential applications across multiple chemotherapy classes and could be extended to other payload types, including immune-modulating agents.

The Affimer platform provides additional scientific differentiation. Affimers are small, engineered scaffold proteins that can be selected to bind specific target proteins with high affinity and specificity. Compared to antibodies, Affimers offer advantages including smaller size, more efficient tissue penetration, stable in vitro performance, ease of multi-specific engineering and lower cost of goods. Applications span therapeutic candidates, diagnostic reagents and research tools. While many Affimer programmes are at earlier stages of development, the platform represents an asset that can be monetised through licensing, partnerships or selective in-house development. The combined scientific foundation supports a credible long-term innovation story.

Conclusion: Why We Rate Avacta a Buy

Avacta Group PLC offers leveraged exposure to a scientifically differentiated oncology platform combined with a stabilising diagnostics commercial base. With pipeline catalysts ahead, focused operational restructuring and a depressed valuation reflecting historical concerns, the risk-reward is asymmetrically attractive for long-term investors. Successful clinical and partnership outcomes would represent material value creation. We therefore rate Avacta Group PLC a Buy for investors comfortable with the inherent volatility of clinical-stage biotech investments.